GBB Attended the 2nd Asia Summit on Global Health

2022-11-14

[HONG KONG, November 14, 2022] The second Asia Summit on Global Health was held in Hong Kong on November 10, 2022, co-organised with the Government of the Hong Kong Special Administrative Region (HKSAR) and the 13th Hong Kong International Medical and Healthcare Fair. John Lee, Hong Kong SAR (HKSAR) Chief Executive, spoke at the summit’s opening ceremony, along with Margaret Fong, Executive Director of the HKTDC, Zsuzsanna Jakab, Deputy Director-General of World Health Organization (WHO); and Cao Xuetao, Vice-Minister of the National Health Commission of the People's Republic of China.




Great Bay Bio (hereinafter referred to as “GBB”) was invited to attend this summit to discuss the latest trends and developments in the healthcare and medical fields with global business leaders and healthcare investors, science and medical experts, healthcare officials, financial specialists and professional service providers.


With the theme of “Charting a New Course in Healthcare through Collaboration”, more than 70 speakers from Japan, South Korea, Israel and other countries in the field of healthcare, representatives of international organizations, representatives of business circles and heads of relevant fields delivered speeches. More than 80 business leaders in the healthcare industry, scientific research professionals, healthcare officials and professional service providers, as well as more than 20,000 participants both in-person and online session discussed the opportunities and development of the global healthcare industry.




Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying artificial intelligence to promote the innovation of bioprocessing innovations, thus solve many pain points such as long drug development cycle, high cost and low success rate. In terms of the rapid development of various biological drugs such as fusion proteins, mAb, and BsAb, GBB’s AI-enabled technology platforms accelerate the entire bioprocessing development attracted the attention of many participants.




In addition, Dr. Kane Qi, Chief Commercial Officer of GBB, attended the ASGH - Shanghai-Hong Kong Cooperation Transition and 2022 Shanghai-Hong Kong Industry-Medical Integration Conference, and gave a speech entitled "Accelerating Bioprocessing Development through AI Technology".




About Asia Summit on Global Health (ASGH)

Asia Summit on Global Health (ASGH) brings together all the stakeholders - from healthcare experts to renowned academia and influential business leaders, together with key industry players, innovative start-ups, investors and policymakers from around the world to exchange insights, explore opportunities and collaborate on the diverse and dynamic healthcare sector.


About Great Bay Bio
Great Bay Bio (GBB), headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal.

The core team of GBB is composed of global talents with expertise in medicine, pharmacy, synthetic biology and AI. With a 3000 m2 R&D center and CMC platform, GBB has successfully pushed several biological drugs into the NDA stage, including national class 1 new drugs. During the three years since its establishment, GBB has applied for more than 30 patents for its AI empowered bioprocesses solutions. The resulting AI platforms were successfully commercialized, enabling GBB to establish long-term cooperation with many domestic and foreign leading enterprises.

GBB has attained the titles of National “High-Tech Enterprise” twice in a row by the National High-Tech Enterprise Certification Management Leading Group Office, “Sprouts List Most Valuable Enterprises for Investment in China for the Year 2020 by the Zero2IPO Group, “Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020” by ZDVC RESEARCH and KPMG China, “Top 15 in the 2021 Merck Greater Bay Area Innovation Bootcamp” and “Spring class of Microsoft accelerator entrepreneurship acceleration plan in 2022”.
Message